


## PRL 2915

<b>Cat. No.:</b>	HY-P4452
<b>CAS No.:</b>	209006-18-8
<b>Molecular Formula:</b>	C <sub>59</sub> H <sub>71</sub> ClN <sub>12</sub> O <sub>8</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	1175.85
<b>Sequence:</b>	{Phe<4-Cl>-[d-Cys]-[β-Ala<3-Py>-[d-Trp]-Lys-{Val<3-Me>-Cys-{2-Nal]-NH <sub>2</sub> (Disulfide bond)
<b>Sequence Shortening:</b>	{F<4-Cl>-[d-C]-[β-A<3-Py>-[d-W]-K-{V<3-Me>-C-{A<3(2-Naph)>-NH <sub>2</sub> (Disulfide bridge:Cys2-Cys7)
<b>Target:</b>	Somatostatin Receptor; Urotensin Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Sealed storage, away from moisture Powder    -80°C    2 years -20°C    1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (85.04 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
1 mM		0.8504 mL	4.2522 mL	8.5045 mL
5 mM		0.1701 mL	0.8504 mL	1.7009 mL
10 mM		0.0850 mL	0.4252 mL	0.8504 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst<sub>2</sub>) antagonist with a K<sub>i</sub> of 12 nM<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC <sub>50</sub> & Target	hsst <sub>2</sub> 12 nM (K <sub>i</sub> )	hsst <sub>3</sub> 100 nM (K <sub>i</sub> )	hsst <sub>5</sub> 520 nM (K <sub>i</sub> )	hsst <sub>4</sub> 895 nM (K <sub>i</sub> )
hsst <sub>1</sub> >1000 nM (K <sub>i</sub> )	hsst <sub>2</sub> 1.8 nM (IC <sub>50</sub> , rat antagonist bioassay versus somatostatin)	rat urotensin II receptor 293 nM (K <sub>i</sub> )	human urotensin II receptor 562 nM (K <sub>i</sub> )	

#### In Vitro

PRL 2915 (0.3-30 nM; 30 min) dose-dependently blocks the development of human urotensin II-induced tonic contractions of

---

rat aortic rings<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Hocart SJ, et al. Highly potent cyclic disulfide antagonists of somatostatin. *J Med Chem.* 1999 Jun 3;42(11):1863-71.

[2]. Rossowski WJ, et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. *Eur J Pharmacol.* 2002 Mar 8;438(3):159-70.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA